Background: Myocardial infarction is accompanied by inflammatory responses that lead to the recruitment of leukocytes and subsequent myocardial damage and healing. Monocyte chemoattractant protein-1 (MCP-1, also known as CC chemokine ligand 2) and its receptor CC chemokine receptor 2 play a central role in the inflammatory response and myocardial injury after ischemia/reperfusion (I/R). Methods: Male adult C57BL/6 mice were anesthetized, and the left anterior descending coronary artery was ligated for 30 min. After reperfusion for 3 days, the ischemia and infarct sizes were determined. Results: The treatment of C57BL/6 mice with anti-MCP-1 reduced the infarct size and lessened myocardial inflammation. Furthermore, anti-MCP-1 prevented I/R-induced caspase-3/7 and -8 activities and reduced apoptosis. The treatment of operated mice with anti-MCP-1 shortly before the induction of myocardial ischemia resulted in a reversal of the infarction and improvements in histologic parameters. Conclusion: These findings demonstrate a pathogenic role for MCP-1 in animal models of I/R and support the consideration of MCP-1 as a therapeutic target in myocardial ischemia.

Keywords:
Ischemia/reperfusion, Monocyte chemoattractant protein-1, Left anterior descending coronary artery, Apoptosis
1.
Yousif NG, Ao L, Cleveland JC, Fullerton DA, Meng X: Aging augments myocardial inflammatory response to ischemia and reperfusion: an obligatory role of TLR-4. Shock 2012;37:32.
2.
Ylä-Herttuala S, Lipton BA, Rosenfeld ME, Särkioja T, Yoshimura T, Leonard EJ, Witztum JL, Steinberg D: Expression of monocyte chemoattractant protein 1 in macrophage-rich areas of human and rabbit atherosclerotic lesions. Proc Natl Acad Sci USA 1991;88:5252-5256.
3.
Wilenky JH, Chang H, Kam JA, Martins WD: Daytime peak incidence of death due to the ischemic heart disease. Am J BioMedicine 2013;2:255-269.
4.
Weber C, Schober A, Zernecke A: Chemokines: key regulators of mononuclear cell recruitment in atherosclerotic vascular disease. Arterioscler Thromb Vasc Biol 2004;24:1997-2008.
5.
Göser S, Ottl R, Brodner A, Dengler TJ, Torzewski J, Egashira K, Rose NR, Katus HA, Kaya Z: Critical role for monocyte chemoattractant protein-1 and macrophage inflammatory protein-1α in induction of experimental autoimmune myocarditis and effective anti-MCP-1 gene therapy. Circulation 2005;112:3400-3407.
6.
Aukrust P, Ueland T, Müller F, Andreassen AK, Nordøy I, Aas H, Kjekshus J, Simonsen S, Frøland SS, Gullestad L: Elevated circulating levels of C-C chemokines in patients with congestive heart failure. Circulation 1998;97:1136-1143.
7.
Behr TM, Wang X, Aiyar N, Coatney RW, Li X, Koster P, Angermann CE, Ohlstein E, Feuerstein GZ, Winaver J: Monocyte chemoattractant protein-1 is upregulated in rats with volume-overload congestive heart failure. Circulation 2000;102:1315-1322.
8.
Charo IF, Taubman MB: Chemokines in the pathogenesis of vascular disease. Circ Res 2004;95:858-866.
9.
Boldron J, Caltabiano S, Debono SD, Thompson R, Scammells M, Westover R, Wu Y, Frugier P: Adhesion molecule expression trigger immune-mediated pathology in lupus-nephritis. Am J BioMedicine 2013;1:49-57.
10.
Oguchi S, Dimayuga P, Zhu J, Chyu KY, Yano J, Shah PK, Nilsson J, Cercek B: Monoclonal antibody against vascular cell adhesion molecule-1 inhibits neointimal formation after periadventitial carotid artery injury in genetically hypercholesterolemic mice. Arterioscler Thromb Vasc Biol 2000;20:1729-1736.
11.
Ni W, Egashira K, Kitamoto S, Kataoka C, Koyanagi M, Inoue S, Imaizumi K, Akiyama C, Nishida KI, Takeshita A: New anti-monocyte chemoattractant protein-1 gene therapy attenuates atherosclerosis in apolipoprotein E-knockout mice. Circulation 2001;103:2096-2101.
12.
Guo J, Van Eck M, Twisk J, Maeda N, Benson GM, Groot PH, Van Berkel TJ: Transplantation of monocyte CC-chemokine receptor 2-deficient bone marrow into ApoE3-Leiden mice inhibits atherogenesis. Arterioscler Thromb Vasc Biol 2003;23:447-453.
13.
Ramote D, Kishony J, Bren L: Role of monocyte chemoattractant protein-1 (MCP-1) in atherosclerosis: signature of monocytes and macrophages. Am J BioMedicine 2014;2:67-79.
14.
Kruglov EA, Nathanson RA, Nguyen T, Dranoff JA: Secretion of MCP-1/CCL2 by bile duct epithelia induces myofibroblastic transdifferentiation of portal fibroblasts. Am J Physiol Gastrointest Liver Physiol 2006;290:G765-G771.
15.
Yousif NG: Fibronectin promotes migration and invasion of ovarian cancer cells through up-regulation of FAK-PI3K/Akt pathway. Cell Biol Int 2014;38:85-91.
16.
Michael LH, Entman ML, Hartley CJ, Youker KA, Zhu J, Hall SR, Hawkins HK, Berens K, Ballantyne CM: Myocardial ischemia and reperfusion: a murine model. Am J Physiol 1995;269:H2147-H2154.
17.
Ha T, Hu Y, Liu L, Lu C, McMullen JR, Shioi T, et al: TLR2 ligands induce cardioprotection against ischemia/reperfusion injury through a PI3K/Akt-dependent mechanism. Cardiovasc Res 2010;87:694-703.
18.
Zhang R, Singh S, Ha X, Cowsik G, Lavezzi O, Caudell H, Ohura R: TLR3 exaggerated sepsis induced cardiac dysfunction via activation of TLR4-mediated NF-κB and TRIF/IRF signaling pathways. Am J BioMedicine 2014;2:94-112.
19.
Hua F, Ha T, Ma J, Li Y, Kelley J, Gao X, et al: Protection against myocardial ischemia/reperfusion injury in TLR4 deficient mice is mediated through a phosphoinositide 3-kinase dependent mechanism. J Immunol 2007;178:7317-7324.
20.
Li C, Ha T, Kelley J, Gao X, Qiu Y, Kao RL, et al: Modulating Toll-like receptor mediated signaling by (1→3)-β-D-glucan rapidly induces cardioprotection. Cardiovasc Res 2003;61:538-547.
21.
Kaikita K, Hayasaki T, Okuma T, Kuziel WA, Ogawa H, Takeya M: Targeted deletion of CC chemokine receptor 2 attenuates left ventricular remodeling after experimental myocardial infarction. Am J Pathol 2004;165:439-447.
22.
Austin EW, Yousif NG, Ao L, Cleveland JC, Fullerton DA, Meng X: Ghrelin reduces myocardial injury following global ischemia and reperfusion via suppression of myocardial inflammatory response. Am J BioMedicine 2013;1:38-48.
23.
Bracale MM, Wonderge RB, Zhou M, Hazen EG: Endotoxemia-suppress cardiac function through dysregulation of mitochondrial biogenesis in mice model. Am J BioMedicine 2014;2:323-336.
24.
Kaya Z, Dohmen KM, Wang Y, Schlichting J, Afanasyeva M, Leuschner F, Rose NR: Cutting edge: a critical role for IL-10 in induction of nasal tolerance in experimental autoimmune myocarditis. J Immunol 2002;168:1552-1556.
25.
Yousif NG, Al-Amran FG: Novel Toll-like receptor-4 deficiency attenuates trastuzumab (Herceptin) induced cardiac injury in mice. BMC Cardiovasc Disord 2011;11:62.
26.
Inoshima I, Kuwano K, Hamada N, Hagimoto N, Yoshimi M, Maeyama T, Takeshita A, Kitamoto S, Egashira K, Hara N: Anti-monocyte chemoattractant protein-1 gene therapy attenuates pulmonary fibrosis in mice. Am J Physiol Lung Cell Mol Physiol 2004;286:L1038-L1044.
27.
Steg J, Slimani H, Hanley TK, Pearson BD, Manson MZ: Directs role of CRP in promoting pathogenesis of atherosclerosis through up-regulation of proinflammatory cytokines. Am J BioMedicine 2014;2:238-244.
28.
Yousif NG, Ao L, Li J, Aly A, Austin E, Fullerton DA, Meng X: Myocardial tissue TLR4 plays a major role in mediating myocardial injury following cold ischemia and reperfusion through up-regulation of MCP-1. J Surg Res 2012;165:181.
29.
Matsuda S, Nakamura J, Eikan S, Meier R, Katz K, Richter J, Mazzon D: XIAP expression attenuated myocardial injury in aging hearts after myocardial ischemia and reperfusion in mice model. Am J BioMedicine 2014;2:400-421.
© 2014 S. Karger AG, Basel
2014
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.